What Lyocontract does

Lyocontract GmbH is a Germany-based contract development and manufacturing organization (CDMO) specializing in GMP-compliant aseptic filling and lyophilization (freeze-drying) of parenteral drugs in vials for human and veterinary use. Founded in 2007 as Fermentation-Biotec GmbH and operational since 2012, the company operates from a single manufacturing site in Ilsenburg, Saxony-Anhalt, equipped with a fully automated Bosch aseptic filling line, custom HOF Sonderanlagenbau freeze-dryers (58 sqm shelf area, 800 kg total ice capacity, CIP/SIP-enabled, including organic solvent processing), a non-GMP development freeze-dryer for cycle scale-up, and an in-house analytical laboratory (HPLC, IR, TOC, UV-VIS, Karl Fischer). It also offers high-speed labeling and packaging (up to 30,000 vials/hour for 2R format) with EU Falsified Medicines Directive serialization capability.

The company's core services are organized around four integrated offerings: aseptic filling, lyophilization, analytical testing, and packaging. It serves pharmaceutical companies globally on a fee-for-service basis, with pricing negotiated per project and not publicly disclosed. Customer acquisition runs through direct B2B sales, industry conferences, and the professional website (available in German and English). The company is FDA compliant and has held GMP certification since 2012.

Lyocontract was majority-owned by Lyomark Pharma GmbH from August 2017 until June 2024, when it was acquired by US-based private equity firm Great Point Partners, who positioned the deal as expanding a healthcare platform into aseptic liquid filling, lyophilization, and injectable drug packaging. The company employs 11–50 people and is led by Managing Director Dr. Tino Galgon.

Name

Lyocontract

Legal name

LYOCONTRACT GmbH

Website

https://lyocontract.de

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Lyocontract GmbH is a German CDMO providing GMP-compliant aseptic filling, lyophilization, analytical testing, and packaging of parenteral drugs in vials for global pharmaceutical clients, operating from a single Ilsenburg site and acquired by Great Point Partners in 2024.

Ownership category

akta.pro rank

Headquarters

HQ city

Ilsenburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Lyocontract operates as a contract development and manufacturing organization (CDMO) providing pharmaceutical manufacturing services on a fee-for-service basis. Services include aseptic filling, lyophilization, analytical testing, and packaging of parenteral drugs in vials for pharmaceutical clients. Revenue is generated through manufacturing contracts with pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Lyocontract is a contract development and manufacturing organization (CDMO) that performs GMP-compliant aseptic filling and freeze-drying (lyophilization) of parenteral drugs in vials, complemented by in-house analytical testing and high-speed packaging with serialization. The company serves pharmaceutical clients in Germany and worldwide as a fee-for-service manufacturer of sterile liquid and freeze-dried injectable products for human and veterinary use.

Product overview

Lyocontract GmbH is a contract manufacturing organization (CMO) offering a comprehensive range of services centered on aseptic filling and freeze-drying of parenteral drugs in vials. The company provides four integrated core services: Aseptic Filling (GMP-compliant sterile vial filling using automated Bosch production line), Lyophilization (freeze-drying using custom HOF freeze-dryers with development capabilities), Analytical Testing (in-house laboratory with HPLC, IR, TOC, Karl Fischer analysis), and Packaging (labeling and serialization). Founded in 2007 and operational since 2012, the company was acquired by Great Point Partners in June 2024, expanding its capabilities in aseptic liquid filling and injectable drug packaging.

Differentiator

Problem solved

Functional benefit

Products and services

• Aseptic Filling GMP-compliant sterile filling of parenteral drugs into vials using a fully automated Bosch production line, for human and veterinary medicinal drugs. The service is targeted at pharmaceutical companies that need to outsource aseptic filling under FDA-compliant and GMP-certified conditions.
• Lyophilization (Freeze-Drying) Freeze-drying of parenteral drugs in vials using custom-made HOF Sonderanlagenbau GMP freeze-dryers (58 sqm shelf area, 800 kg total ice capacity) with CIP/SIP capability, including lyophilization of pharmaceuticals with organic solvents. Includes development and optimization of freeze-drying programs via a non-GMP development freeze-dryer. Targeted at pharmaceutical companies requiring commercial or development-scale lyophilization capacity.
• Analytical Testing In-house analytical services using 4 HPLC units, IR spectrophotometer, TOC analyzer, UV-VIS spectrometer, and Karl Fischer titrator for quality control of raw materials, in-process controls, and final product analysis, as well as process and method transfers and process and method validation. Targeted at pharmaceutical companies needing integrated QC and regulatory support for parenteral drug manufacturing.
• Packaging and Serialization Full-service packaging and labeling using a Brausch + Ströbel labeling machine (capacity 13,800 vials/hour for 100H format or 30,000 vials/hour for 2R format) and a KBA Metronic box printer, including variable data printing (batch number, expiration date) and serialization of folding boxes per EU Directive 2011/62/EU (Falsified Medicines Directive). Targeted at pharmaceutical companies needing compliant, high-speed packaging and anti-counterfeiting serialization for parenteral drug products.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Lyomark Pharma GmbHmajorStrategic or Co-development Partner · 1 August 2017In August 2017, Lyomark Pharma GmbH became the majority shareholder of LYOCONTRACT GmbH. Both companies are privately held and continue to be managed independently. This partnership provides strategic alignment within the pharmaceutical manufacturing sector.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Market position

Strengths1 record

Weaknesses4 records

Competitive moat3 records

Customer concentration

• LinkedInlinkedin.com/company/lyocontract-gmbh

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyocontract